BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.
Fact Check: Edited BioNTech CEO clip resurfaces with false vaccine claim
The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...
Fintel on MSN2d
Truist Securities Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy Recommendation
Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () ...
Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
FiercePharma9d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
BioNTech initiated with a Buy at Truist
Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it ...
BioNTech SE ADR falls Wednesday, underperforms market
The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...
stocknews6d
3 Genomic Stocks Unlocking the Secrets of DNA
Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...
Geode Capital Management LLC Lowers Stock Position in BioNTech SE (NASDAQ:BNTX)
Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...
The Motley Fool2d
BioNTech Se (NASDAQ: BNTX)
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...